Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkEfficacy of Preoperative mFOLFIRINOX vs. mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

The 18-month OS rates in this trial were:

  • 66.7% for neoadjuvant mFOLFIRINOX
  • 47.3% for neoadjuvant mFOLFIRINOX and hypofractionated radiotherapy
  • 87.5% for mFOLFIRINOX followed by pancreatectomy
  • 78.9% for mFOLFIRINOX plus radiotherapy followed by pancreatectomy

The authors state these results “suggest that mFOLFIRINOX represents a reference neoadjuvant treatment regimen for borderline resectable pancreatic cancer; however, the role of radiotherapy in this setting remains undefined.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form